Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives

25 Nov 2021

Abstract excerpt

Triple negative tumors represent 15% of breast cancer and are characterized by the lack of estrogen receptors, progesterone receptor, and HER2 amplification or overexpression. Approximately 25% of patients diagnosed with triple negative breast cancer carry a germline BRCA1 or BRCA2 mutation. They have an aggressive biology, and chemotherapy has been the mainstay of treatment for a long time. Despite intensive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34900718
DOI: 10.3389/fonc.2021.769280

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future PerspectivesPMID 34900718Read ↗

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.Semantic proximity Read ↗

An Overview of PARP Inhibitors for the Treatment of Breast CancerSemantic proximity Read ↗

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistanceSemantic proximity Read ↗

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancersSemantic proximity Read ↗

PARP inhibitors in the management of breast cancer: current data and future prospects.Semantic proximity Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Evidence to date: talazoparib in the treatment of breast cancerSemantic proximity Read ↗

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.Semantic proximity Read ↗

Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancerSemantic proximity Read ↗

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.Semantic proximity Read ↗

Advances in The Use of Parp Inhibitors For Brca1/2-Associated Breast Cancer: TalazoparibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.